Net Cash Provided by (Used in) Financing Activities in USD of VYNE Therapeutics Inc. from 2015 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
VYNE Therapeutics Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and change rate from 2015 to Q1 2025.
  • VYNE Therapeutics Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was -$87K, a 1640% decline year-over-year.
  • VYNE Therapeutics Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was -$141K, a 100% decline from 2023.
  • VYNE Therapeutics Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $82.4M, a 4885% increase from 2022.
  • VYNE Therapeutics Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $1.65M, a 95.8% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

VYNE Therapeutics Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 -$87K -$82K -1640% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025
Q1 2024 -$5K +$212K +97.7% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025
Q1 2023 -$217K -$1.75M -114% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024
Q1 2022 $1.53M -$72M -97.9% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023
Q1 2021 $73.5M +$73.4M +52402% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022
Q1 2020 $140K +$124K +775% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021
Q1 2019 $16K -$125M -100% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020
Q1 2018 $125M +$125M 01 Jan 2018 31 Mar 2018 10-Q 02 May 2019
Q1 2017 $0 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018

VYNE Therapeutics Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$141K -$82.5M -100% 01 Jan 2024 31 Dec 2024 10-K 06 Mar 2025
2023 $82.4M +$80.7M +4885% 01 Jan 2023 31 Dec 2023 10-K 06 Mar 2025
2022 $1.65M -$38.1M -95.8% 01 Jan 2022 31 Dec 2022 10-K 01 Mar 2024
2021 $39.8M -$22M -35.6% 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2023
2020 $61.8M +$13.9M +28.9% 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2022
2019 $48M -$44.4M -48.1% 01 Jan 2019 31 Dec 2019 10-K 04 Mar 2021
2018 $92.4M +$42.9M +86.6% 01 Jan 2018 31 Dec 2018 10-K 04 Mar 2021
2017 $49.5M +$49.5M 01 Jan 2017 31 Dec 2017 10-K 03 Mar 2020
2016 $0 -$47.7M -100% 01 Jan 2016 31 Dec 2016 10-K 28 Feb 2019
2015 $47.7M 01 Jan 2015 31 Dec 2015 10-K 28 Mar 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.